-+ 0.00%
-+ 0.00%
-+ 0.00%

Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio

PUBT·07/20/2026 17:44:46
Listen to the news
Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio
  • Valion Bio disclosed a new clinical expansion for Entolimod into supportive oncology via a Sheba Medical Center-funded trial in cancer patients.
  • Sheba, ranked No. 7 globally, plans to run the study in up to 10 adults receiving high-dose irradiation for a rare cancer.
  • Program targets radiation-induced neutropenia, opening a second development pathway beyond the FDA Animal Rule effort for acute radiation syndrome.
  • IRB decision targeted for Q3 2026; first patient enrollment expected Q4 2026–Q1 2027; interim data slated for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.